Scarica l'app Stockscreener
781.98
0.50%
3.91
Dopo l'orario di chiusura:
781.00
-0.98
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$778.07
Aprire:
$778.17
Volume 24 ore:
1.62M
Relative Volume:
0.48
Capitalizzazione di mercato:
$703.25B
Reddito:
$40.86B
Utile/perdita netta:
$8.37B
Rapporto P/E:
84.54
EPS:
9.25
Flusso di cassa netto:
$-2.28B
1 W Prestazione:
-0.15%
1M Prestazione:
-3.85%
6M Prestazione:
-12.93%
1 anno Prestazione:
+26.60%
Intervallo 1D:
$775.53
$785.84
Intervallo di 1 settimana:
$764.30
$787.00
Portata 52W:
$609.59
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
781.98 | 703.25B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
87.65 | 389.28B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.19 | 347.16B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
181.22 | 320.24B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
99.14 | 250.79B | 63.17B | 12.15B | 14.84B | 4.77 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly's Zepbound set to eclipse Wegovy in U.S. obesity drug marketCHOSUNBIZ - 조선비즈
Eli Lilly's (NYSE:LLY) Dividend Will Be Increased To $1.50 - Yahoo Finance
Prediction: These 3 Healthcare Stocks Will Soar in 2025 - The Motley Fool
Eli Lilly & Co. stock rises Friday, still underperforms market - MarketWatch
Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: Evaluate - FiercePharma
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Eli Lilly Joins FDA Lawsuit Over Compounded Obesity Drugs, Seeks 'Swift End' And 'To Protect Its Interests' - Yahoo Finance
Pharma giant seeks to join lawsuit against FDA over weight loss drugs - The Hill
Eli Lilly Slams Suit Alleging Shortage Of Weight-Loss Drug - Law360
Lilly seeking to join lawsuit over compounded GLP-1 drugs (LLY:NYSE) - Seeking Alpha
Eli Lilly Moves to Join Lawsuit Over Weight Loss Drug Shortage - Bloomberg Law
Lilly asks to join lawsuit over compounded versions of its weight-loss drugs - Reuters
Eli Lilly Stock: Is LLY Stock A Buy After FDA Pushes Back On Compounded Knockoffs? - Investor's Business Daily
Eli Lilly Stock Upgraded to "Buy" as Analysts Boost Price Target to $1,250 - Yahoo Finance
Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get them - Quartz
$100 Invested In Eli Lilly 15 Years Ago Would Be Worth This Much Today - Benzinga
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver - Forbes
Jim Cramer’s Take on Eli Lilly and Company (LLY): Bold Predictions for the Future - Insider Monkey
Eli Lilly Unusual Options Activity - Benzinga
Eli Lilly, Novo Nordisk Went Head-to-Head on Weight-Loss Drugs in 2024. There’s a Clear Winner. - Barron's
Lupin Acquires Huminsulin from Eli Lilly | - Chemical Industry Digest
Is Eli Lilly and Company (LLY) the Best Low Volatility Stock to Buy Right Now? - Insider Monkey
Pharma stock in green after acquiring Huminsulin drug from Eli Lilly to boost diabetes treatment - Trade Brains
Eli Lilly’s Zepbound drug likely to dominate global obesity market: Report By IANS - Investing.com India
Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio - Indian Pharma Post
Why Eli Lilly (LLY) Dipped More Than Broader Market Today - Yahoo Finance
Is Eli Lilly and Company (LLY) the Best Pharma Dividend Stock to Buy In 2024? - Insider Monkey
Lupin To Acquire Huminsulin In India From Eli Lily To Augment Diabetes Portfolio - NDTV Profit
Lupin acquires 'Huminsulin' in India from Eli Lilly and Co - The Economic Times
Is Eli Lilly Stock a Buy? - The Motley Fool
2024 Newsmaker: Lilly CEO David Ricks - Indianapolis Business Journal
Eli Lilly and Company (NYSE:LLY) Stock Price Down 0.8%Here's Why - MarketBeat
Tesla's Musk Uses Weight-Loss Drugs as Eli Lilly and Novo Nordisk Dominate the Market - Yahoo Finance
Eli Lilly and Company (NYSE:LLY) Trading Down 0.2%What's Next? - MarketBeat
Why Elon Musk Prefers Eli Lilly’s (LLY) Mounjaro over Novo Nordisk’s Ozempic - TipRanks
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear. - The Motley Fool
Jim Cramer Says Eli Lilly and Company (LLY)’s ‘Going To Win’ - Insider Monkey
Elon Musk says he prefers Lilly’s Mounjaro over Novo’s Ozempic - Seeking Alpha
Eli Lilly and Company (NYSE:LLY) Trading Down 0.1%Should You Sell? - MarketBeat
Jim Cramer Says Novo Nordisk A/S (NVO) Can’t Exceed Eli Lilly - Yahoo Finance
Eli Lilly and Co (LLY) Is Among Billionaire Coleman’s Top Picks - Yahoo Finance
Eli Lilly and Company (NYSE:LLY) Rating Lowered to Hold at StockNews.com - MarketBeat
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices - Yahoo! Voices
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
Stock Quote & Chart - Investors | Eli Lilly and Company
Lilly obesity drug Mounjaro to be offered in Britain's NHS after watchdog nod - Reuters
With EPS Growth And More, Eli Lilly (NYSE:LLY) Makes An Interesting Case - Yahoo Finance
Is Now a Good Time to Buy the Dip in Eli Lilly Stock? - AOL
Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength. - Yahoo! Voices
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound - Investopedia
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):